FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC By Ogkologos - January 24, 2025 718 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Urine test for bladder cancer being developed July 2, 2021 Why consistent and funded cancer policies are key to improving cancer... November 1, 2022 Immunotherapy Drug Cemiplimab Approved for Advanced Squamous Cell Skin Cancer October 19, 2018 FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer... October 16, 2023 Load more HOT NEWS Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine... Biomarker Analyses in Patients with HER2-positive or HER2-low Gastric and Gastro-oesophageal... One Family’s Mission to Stop Hair Loss from Chemotherapy: Your Stories... ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of...
